Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). CEO Khattar base salary raised 3% to $1,067,100; 2025 bonus $846,930; granted 341,610 options + 204,966 PSUs.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CEO Khattar base salary raised 3% to $1,067,100; 2025 bonus $846,930; granted 341,610 options + 204,966 PSUs
- CFO Dec salary raised ~4% to $525,100; 2025 bonus $233,894; granted 17,500 options, 3,000 RSUs, 3,500 PSUs
- All SVP base salaries raised ~3-4%; 2026 bonus targets unchanged (35–40% of base for SVPs, 75% for CEO)
- Stock option exercise price set at $50.20/share; all options and RSUs vest annually over 4 years
- PSU vesting tied to performance goals at Committee's sole discretion: adds alignment but introduces dilution risk if targets are met
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.